18- β-glycyrrhetinic acid-loaded polymeric nanoparticles attenuate cigarette smoke-induced markers of impaired antiviral response in vitro
This study explores the therapeutic potential of an advanced drug delivery system encapsulating 18-β-gly in poly lactic-co-glycolic acid (PLGA) nanoparticles in addressing the impaired antiviral immunity observed in smokers and COPD patients. Exposure of BCi-NS1.1 human bronchial epithelial cells to cigarette smoke extract (CSE) resulted in reduced expression of critical antiviral chemokines (IP-10, I-TAC, MIP-1α/1β), mimicking what happens in smokers and COPD patients. Treatment with 18-β-gly-PLGA nanoparticles partially restored the expression of these chemokines, demonstrating promising therapeutic impact. The nanoparticles increased IP-10, I-TAC, and MIP-1α/1β levels, exhibiting potential in attenuating the negative effects of cigarette smoke on the antiviral response. This study provides a novel approach to address the impaired antiviral immune response in vulnerable populations, offering a foundation for further investigations and potential therapeutic interventions. Further studies, including a comprehensive in vitro characterization and in vivo testing, are warranted to validate the therapeutic efficacy of 18-β-gly-PLGA nanoparticles in respiratory disorders associated with compromised antiviral immunity.PMID:38603841 | DOI:10.1016/j.prp.2024.155295
Source: Pathology, Research and Practice - Category: Pathology Authors: Gabriele De Rubis Keshav Raj Paudel Stewart Yeung Siddiq Mohamad Swathi Sudhakar Sachin Kumar Singh Gaurav Gupta Philip Michael Hansbro Dinesh Kumar Chellappan Brian Gregory George Oliver Kamal Dua Source Type: research
More News: Antidoxidants | Cancer | Cancer & Oncology | Chronic Obstructive Pulmonary | Epithelial Cancer | Licorice | Lung Cancer | Nanotechnology | Pathology | Respiratory Medicine | Smokers | Study